Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IRON with free AI briefings, catalyst countdowns, and dilution alerts.

IRON · Disc Medicine, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$682.8M Cash on Hand
48.5mo Cash Runway
Follow IRON by email Get an email when IRON reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IRON, unsubscribe in one click. Privacy

📣 What IRON Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bitopertin Erythropoietic Protoporphyria Phase 2/3 · NCT05883748 Enrolling by invitation
Selcodebart (DISC-0974) Inflammatory Bowel Disease (IBD) Phase 2 · NCT07368972 Recruiting
Anti-TMPRSS6 Monoclonal Antibody DISC-3405 Polycythemia Vera (PV) Phase 2 · NCT06985147 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IRON holds $682.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $42.2M/quarter from operations, an estimated runway of 48.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IRON files for a raise →

👥 Who Owns IRON

Insiders 1.3% Other 5%+ holders 6.5% Institutions (318 holders) 92.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 4,875,473 10.71% 2026-06-30
AI DMI LLC 5%+ holder (13D) 2,943,410 6.46% 2026-10-22
RA Capital Management, L.P. Institution (13G, 5%+) 2,228,924 4.89% 2025-12-30
John D Quisel
Chief Executive Officer, Director · +340,297 options
Insider 262,064 0.58% 2026-09-15
Pamela Stephenson
Chief Commercial Officer · +25,500 options
Insider 80,998 0.18% 2026-02-17
Jean M. Franchi
Chief Financial Officer · +25,500 options
Insider 64,333 0.14% 2026-04-13
William Jacob Savage
Chief Medical Officer · +25,500 options
Insider 63,445 0.14% 2026-11-10
Jonathan Yen-Wen Yu
Chief Operating Officer · +71,298 options
Insider 54,324 0.12% 2026-08-24
Rahul Khara
Chief Legal Officer · +96,574 options
Insider 52,324 0.11% 2026-08-06
Kevin Bitterman
Director · +6,212 options
Insider 12,991 0.03% 2026-10-19

Share count 45,540,842 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IRON picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRON and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.